News
Many companies face FDA complete response letters due to ongoing chemistry, manufacturing, and controls, or CMC, and ...
The CRL was given because the FDA did not consider the phase 1/2 IGNYTE trial to be an adequate and well-controlled clinical ...
Rosen Law Firm, a global investor rights law firm, announces it has filed a class action lawsuit on behalf of purchasers of the securities of Replimune Group, Inc. (NASDAQ: REPL) between November 22, ...
During a live event, Mark Yarchoan, MD, and participants reviewed adverse event management for 3 different combination ...
Dispatch Bio launched with $216 million – backed primarily by Parker Institute for Cancer Immunotherapy, founded by entrepreneur Sean Parker, and ARCH Venture Partners. SAB BIO announced an ...
A 55-year-old man’s swollen toes and fingers turned out to have a much stranger explanation than expected. In a recent case ...
The gene therapy developer is cutting 30% of its workforce. Elsewhere, Abivax secured a major cash infusion, while Novartis and Eli Lilly struck small research deals.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results